What value do JAK inhibitors have in treating rheumatoid arthritis?

References

• Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017 Feb 21;46(2):183–196.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jan 22:annrheumdis-2019-216655. doi10.1136/annrheumdis-2019-216655.
   Google Scholar
• Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013 Feb 9;381(9865):451–460.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 31;374(13):1243–1252.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):2513–2524.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019 Jul 23;322(4):315–325.
   PubMed Web of Science ®Google Scholar
• Kerschbaumer A, Sepriano A, Smolen JS, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis.
   Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017 Feb 16;376(7):652–662.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019 Jul 9;71:1788–1800.
   Web of Science ®Google Scholar
• Combe B, Kivitz A, Tanaka Y, et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Arthritis Rheumatol. 2019;71(suppl 10). [cited 2020 Jun 13]. Available fromhttps://acrabstracts.org/abstract/efficacy-and-safety-of-filgotinib-for-patients-with-rheumatoid-arthritis-with-inadequate-response-to-methotrexate-finch1-primary-outcome-results/
   Google Scholar
• Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 Jul 29;390(10093):457–468.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Fautrel B, Keystone EC, et al. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Ann Rheum Dis. 2019 Jul;78(7):890–898.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019 Nov;78(11):1454–1462.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Genovese MC, Haraoui B, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019 Feb;78(2):171–178.
   PubMed Web of Science ®Google Scholar
• Richez C, Morel J, Cornec D, et al. Practical management of patients on Janus kinase inhibitor (JAKi) therapy: practical fact sheets drawn up by the rheumatism and inflammation club (CRI), a group endorsed by the French society for rheumatology (SFR). Joint Bone Spine. 2019 Oct;86(Suppl 1):eS2–eS103.
   PubMedGoogle Scholar
• Sepriano A, Regel A, van der Heijde D, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3(1):e000396.
   PubMed Web of Science ®Google Scholar
• Xie W, Huang Y, Xiao S, et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019 Aug;78(8):1048–1054.
   PubMed Web of Science ®Google Scholar
• Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019 Sep;71(9):1450–1459.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019 Jul;71(7):1042–1055.
   PubMed Web of Science ®Google Scholar
• Richez C, Truchetet ME, Kostine M, et al. Efficacy of baricitinib in the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2017 Sep;18(13):1399–1407.
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014 Jun 19;370(25):2377–2386.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Durez P, Schett G, et al. Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. Clin Rheumatol. 2018 Sep;37(9):2381–2390.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R, Takeuchi T, Pangan AL, et al. A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naive patients with active rheumatoid arthritis. Rheumatology. 2019 Apr;58:64.
   Web of Science ®Google Scholar
• Barroso NS, Miller EZ, Furst DE. A case series on patients on tofacitinib in combination with a biologic. J Clin Rheumatol. 2018 Sep;24(6):349–351.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Apr;20(4):400–402.
   PubMed Web of Science ®Google Scholar